Back to other trials
Vaccine
Vaccine
RSV + Flu
Respiratory Syncytial Virus (RSV) is a common respiratory virus that typically causes mild, cold-like symptoms. However, it can be more severe in certain populations, such as infants, young children, and older adults, especially those with underlying health conditions. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under one year of age in the United States. The virus spreads through respiratory droplets when an infected person coughs or sneezes and can also survive on surfaces for several hours, making good hygiene practices crucial in preventing its spread. There is no specific treatment for RSV infections, and care is generally supportive. Efforts to develop a vaccine are ongoing, highlighting the significant impact of the virus on public health.
RSV + Flu
ACRA is looking for participants who:

• are at least 65 years old

• have not been diagnosed with influenza, RSV, or hMPV infection within 6 months of Visit 1

• have not received any RSV and/or influenza vaccine within 6 months of Visit 1
Compensation
up to $650
Age
≥65
Duration
6 months
Visits
3 in-office/
1 by phone